Dysregulation of Protein Phosphorylation/Dephosphorylation
in Alzheimer's Disease: A Therapeutic Target by Gong, Cheng-Xin et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2006, Article ID 31825, Pages 1–11
DOI 10.1155/JBB/2006/31825
ReviewArticle
Dysregulation of Protein Phosphorylation/Dephosphorylation
in Alzheimer’s Disease: A Therapeutic Target
Cheng-Xin Gong,Fei Liu, Inge Grundke-Iqbal, and Khalid Iqbal
Department of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road,
Staten Island, NY 10314-6399, USA
Received 8 November 2005; Revised 12 December 2005; Accepted 3 January 2006
Studies during the last two decades have provided new insights into the molecular mechanism of Alzheimer’s disease (AD). One of
the milestone ﬁndings in AD research was the demonstration that neuroﬁbrillary degeneration characterized by tau pathology is
central to the pathogenesis of AD and other tauopathies and that abnormal hyperphosphorylation of tau is pivotal to neuroﬁbril-
lary degeneration. This article reviews the recent research advances in tau pathology and the underlying dysregulation of the pro-
tein phosphorylation/dephosphorylation system. An updated model of the mechanism of neuroﬁbrillary degeneration is also pre-
sented, and a promising therapeutic target to treat AD by correcting dysregulation of protein phosphorylation/dephosphorylation
is discussed.
Copyright © 2006 Cheng-Xin Gong et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Although Alzheimer’s disease (AD) and its main brain histo-
pathology, that is, senile plaques and neuroﬁbrillary tangles
(NFTs),weredescribedacenturyago,signiﬁcantresearchad-
vances in the disease began only a few decades ago. The dis-
coveries of the major protein components of senile plaques
as amyloid β-peptide [1, 2] and of NFTs as abnormally hy-
perphosphorylated tau [3, 4] in the 1980s initiated a new era
of AD research. Since then, much research has focused on
the molecular mechanisms of initiation and formation of the
senile plaques and NFTs and their roles in the pathogene-
sis of AD. Evidence accumulated in the last two decades in-
dicates that malprocessing of both tau and β-amyloid pre-
cursor protein, which produces β- p e p t i d e ,i sp i v o t a l ,i fn o t
central, to the molecular mechanism of AD. The severity of
dementia symptoms in AD strongly correlates to the num-
ber of NFTs, but not of senile plaques, in AD brains [5–9],
suggesting that tau pathology might be associated with the
disease mechanism more directly. Abnormal hyperphospho-
rylation of tau and its deposits in the brain is also seen in
several other neurodegenerative diseases that are collectively
named tauopathies (for review, see [10, 11]). The discovery
of tau mutations that cause hereditary frontotemporal de-
mentia and Parkinsonism linked to chromosome 17 (FTDP-
17) [12–14] further indicates that tau abnormality alone is
suﬃcient to produce dementia. Therefore, for developing
rational therapeutic treatment of AD, it is essential to under-
stand the molecular mechanism by which tau abnormalities
lead to neuroﬁbrillary degeneration.
Because tau aggregated in the brain of AD and all other
tauopathies is always abnormally hyperphosphorylated, nu-
merous studies have focused on the roles of the abnor-
mal hyperphosphorylation and the mechanism leading to
tau hyperphosphorylation. Recent studies demonstrate that
it is the abnormal hyperphosphorylation that makes tau
lose its normal function to stimulate microtubule assem-
bly, gain toxic activity, and aggregate into NFTs [15–23]. In
addition to tau, several other brain proteins such as neu-
roﬁlaments, microtubule-associated protein (MAP) 1B, β-
tubulin, and β-catenin are also found to be hyperphospho-
rylated [24–27], suggesting that the protein phosphoryla-
tion/dephosphorylation system might be dysregulated in AD
brain. This article attempts to review the recent advances in
this respect. Because abnormally hyperphosphorylated tau is
pivotal to AD and has been extensively studied, this review
focuses on tau hyperphosphorylation. Prevention and rever-
sal of abnormal hyperphosphorylation of tau as a potential
promising therapeutic strategy is also discussed.
TAU PROTEIN
Tau was ﬁrst discovered by Weingarten et al [28]a sam i -
crotubule-associated protein that stimulates microtubule2 Journal of Biomedicine and Biotechnology
assembly. There was not much research interest in tau pro-
tein until a decade later, when it was found to make up the
paired helical ﬁlaments (PHFs) that form NFTs in AD brain
[3, 4, 29]. Human tau gene was found on the long arm of
chromosome 17 (position 17q21) and was found to contain
16 exons [30]. This single tau gene encodes six tau isoforms
in adult human brain as a result of alternative splicing of its
mRNA[31].Thesixisoformsoftaudiﬀerfromeachotherby
thepresenceorabsenceofoneortwoinserts(29or58amino
acids) in the N-terminal part and by the presence of either
three or four repeats in the C-terminal half. The N-terminal
insertsarehighlyacidic.TherepeatsintheC-terminalhalfof
tau are the domains that bind to microtubules [32–34]. The
region upstream of the microtubule-binding domains con-
tains many proline residues and, hence, is called the proline-
rich region.
The best-known biological functions of tau are to stimu-
latemicrotubuleassemblyandtostabilizemicrotubulestruc-
ture. Tau binds to microtubules via its microtubule-binding
domains located at the C-terminal half of the molecule [32–
34]. The N-terminal part projects from the microtubule sur-
face, where it may interact with other cytoskeletal elements
and the plasma membrane [35, 36]. Each of the six tau iso-
forms possibly has its particular physiological roles and dif-
ferential biological activities, because they are diﬀerentially
expressed during development and have diﬀerent activities
to stimulate microtubule assembly [37, 38]. Only the short-
est isoform of tau is expressed in fetal brain, whereas all six
isoforms are seen in adult brain [39, 40]. In addition to stim-
ulating microtubule assembly, several studies have suggested
that tau may have other physiological functions. It appears
to interfere with binding of kinesin and kinesin-like mo-
tors to microtubules, leading to a preferential inhibition of
plus-end-directed axonal transport [41]. Overexpression of
tau inhibits kinesin-dependent traﬃcking of vesicles, mito-
chondria, and endoplasmic reticulum [42]. This may explain
the symptoms of amyotrophic lateral sclerosis with neuroﬁl-
ament accumulation in motor neurons of several transgenic
models of tau overexpression [43–46]. Tau has been found
to interact with mitochondria [47], plasma membrane [36],
and nucleic acids [48, 49] ,s u g g e s t i n gt h a ti tm a ya c ta sam e -
diator between microtubules and these organelles. Tau also
appears to interact with src-family nonreceptor tyrosine ki-
n a s e ss u c ha sf y n[ 50, 51] and phospholipase C-γ [52, 53]vi a
its proline-rich region. These data suggest that tau may also
play a role in the signal transduction pathways involving src-
family tyrosine kinases and phospholipase C-γ.H o w ev e r ,t h e
physiological signiﬁcance of these interactions remains to be
elucidated.
As early as 1977, tau was found to be a phosphopro-
tein [54]. In 1984, it was demonstrated that phosphorylation
of tau negatively regulates its activity in promoting micro-
tubule assembly [55]. Because tau is abnormally hyperphos-
phorylated in AD and other tauopathies, tau phosphoryla-
tion has been studied extensively. Normal brain tau contains
2 or 3 moles of phosphates per mole of tau [56–58]. Studies
on human brain biopsy tissue indicated that several serine
and threonine residues of tau are normally phosphorylated
atsubstoichiometricallevels[59,60].Anormallevelofphos-
phorylation appears to be required for tau’s optimal func-
tion, whereas the hyperphosphorylated tau loses its biologi-
cal activity [15, 16, 61–69].
ABNORMAL HYPERPHOSPHORYLATION OF
TAU IN AD BRAIN
The discovery that tau aggregated in AD brain is abnor-
mally hyperphosphorylated has stimulated many studies on
the extent and sites of tau hyperphosphorylation and their
role in the pathogenesis of AD. The phosphorylation level of
tau isolated from autopsied AD brains is 3- to 4-fold higher
than that from normal human brains [56–58]. In addition,
the hyperphosphorylated tau is accumulated in both brains
[70, 71] and cerebral spinal ﬂuid [72–80] of individuals with
AD. All six isoforms of tau are aggregated into PHFs in the
abnormally hyperphosphorylated forms in AD brains [3, 4,
31, 81]. To date, at least 37 serine and threonine residues
have been found to be phosphorylated in PHF-tau (for re-
view, see [82]). These residues include Thr39, Ser46, Thr69,
Thr123, Ser137, Thr153, Thr175, Thr181, Ser198, Ser199,
Ser202, Thr205, Ser208, Ser210, Thr212, Ser214, Thr217,
Thr231, Ser235, Ser237, Ser238, Ser241, Ser262, Ser285,
Ser305, Ser324, Ser352, Ser356, Ser396, Ser400, Thr403,
Ser404, Ser409, Ser412, Ser413, Ser416, and Ser422. Many
of these residues are also phosphorylated in normal hu-
man brains without NFTs at smaller extents, but they are
rapidly dephosphorylated during postmortem delay and tis-
sue processing [59, 60]. However, the phosphate groups at
these sites are not readily dephosphorylated during the post-
mortem period and tissue processing of AD brain, proba-
bly because of the deﬁcient protein phosphatase activities
[83–89]. Some of the phosphorylation sites seen in PHF-
tau are not phosphorylated at all in normal brains. These
sitesincludeThr212/Ser214,Thr231/Ser235[90],andSer422
[91, 92].
Because all of the previously identiﬁed phosphorylation
sites of normal tau and PHF-tau are at either serine or thre-
onine residues, it was thought that tau was phosphorylated
only at serine and threonine residues. However, recent stud-
ies suggest that tau in developing brain and in AD brain
is also phosphorylated at tyrosine residues. The src-family
nonreceptor tyrosine kinase fyn can bind to and phospho-
r y l a t et a ui nv i t r oa n di nt r a n s f e c t e dc e l l s[ 50, 51, 93]. The
phosphorylation site of tau was mapped as Tyr18. Tyrosine
phosphorylated tau at this position is also seen immuno-
histochemically in the brain of transgenic mice that express
mutated human tauP301L [51]. Williamson et al [94]d e m o n -
strated that in primary human and rat brain cortical cultures
tau is phosphorylated at Tyr 29 upon treatment with Aβ.Th e
tyrosine phosphorylation of tau appears rapid and transient.
Interestingly, antibodies speciﬁc to tyrosine phosphorylated
tau labeled puriﬁed PHF-tau, but not normal tau, suggest-
ing that PHF-tau is phosphorylated at the tyrosine residues
[93, 94]. In addition, Tyr394 was also found to be phospho-
rylatedinPHF-tauandintaufromfetalbrains,andthephos-
phorylation at this site is catalyzed by another nonreceptorCheng-Xin Gong et al 3
tyrosine kinase c-Abl [95]. It is not clear if the phosphory-
lation at any of the above tyrosine residues is stoichiometri-
cally signiﬁcant. Therefore, whether the tyrosine phosphory-
lation of tau has any pathophysiological relevance remains to
be elucidated.
Numerous studies have demonstrated the important role
of abnormal hyperphosphorylation of tau in its aggrega-
tion into NFTs and in Alzheimer’s neuroﬁbrillary degener-
ation. In cultured cells, hyperphosphorylation of tau after
treatment with phosphatase inhibitors impairs its activity
to bind to microtubules and induces ﬁlamentous aggrega-
tion of tau [21]. Pseudohyperphosphorylated tau that sim-
ulates abnormally hyperphosphorylated tau by mutation of
serine or threonine residues into glutamate at selected AD-
related sites exerts a cytotoxic eﬀect, whereas wild-type tau
is neutral [22]. In contrast, neurons from tau-knockout mice
are resistant to Aβ-induced neurotoxicity [96]. Overexpres-
sion of human tau in combination with phosphorylation by
Drosophila GSK-3β homologue Shaggy, but not tau overex-
pression alone, exacerbates tau-induced neurodegeneration
and results in the formation of NFT-like ﬁlamentous tau ag-
gregates[23]. This study shows a causal relationship between
tau hyperphosphorylation and neuroﬁbrillary degeneration
in vivo. A study in Disabled-1 (an adapter protein) knockout
mice further demonstrates that tau hyperphosphorylation
causes early death of the animals [97]. Most importantly, tau
in inclusions of all tauopathies in human and animal mod-
e l si sa l w a y sh y p e r p h o s p h o r y l a t e d( f o rr e v i e w s ,s e e[ 11, 98]).
Abnormal hyperphosphorylation of tau appears to precede
its aggregation into NFTs in AD brain [57, 99–101]. Taken
together, these studies suggest that the abnormal hyperphos-
phorylation of tau is crucial to neuroﬁbrillary degeneration
in AD and other tauopathies.
The largest isoform of human brain tau (441 amino
acids) contains 80 serine and threonine residues and ﬁve ty-
rosine residues [31]. Phosphorylation at nearly half of these
residues has been reported in PHF-tau (see [82]f o rr e -
view). Many studies have demonstrated that phosphoryla-
tion of tau at diﬀerent sites has diﬀerent impacts on its bi-
ological function and on its pathogenic role. For instance,
a quantitative in vitro study demonstrated that phospho-
rylation of tau at Ser262, Thr231, and Ser235 inhibits its
binding to microtubules by ∼35%, ∼25%, and 10%, re-
spectively [102]. In cultured cells, phosphorylation of tau
at Ser214 and Ser262 decreases its binding to microtubules
and appears to inhibit its assembly to ﬁlaments [103]. In
vitro kinetic studies of the binding between hyperphospho-
rylated tau and normal tau suggest that phosphorylation
of tau at Ser199/Ser202/Thr205, Thr212, Thr231/Ser235,
Ser262/Ser356, and Ser422 are among the critical phospho-
rylation sites that convert tau to a toxic molecule to sequester
normal MAPs from microtubules [19]. Further phosphory-
lation at Thr231, Ser396, and Ser422 promotes self-assembly
of tau into ﬁlaments. Similarly, tau mutated at Ser396 and
Ser404 (changing Ser into Glu) to mimic phosphoserine is
more ﬁbrillogenic than wild-type tau [104], and a tau con-
struct in which Ser422 is mutated to Glu shows a signiﬁ-
cantly increased propensity to aggregate [105]. Consistent
withtheseobservationsisthatmutationofSer422toAlapre-
vents Aβ-induced tau aggregation [106]. These results sug-
gest that phosphorylation of Ser422 may play a key role in
tau ﬁlament formation in vivo.
An important question is, by what mechanism is the
tau abnormality involved in the pathological cascades that
lead to neurodegeneration in AD and other tauopathies.
Does a hyperphosphorylation-induced defect in its activity
to stimulate microtubule-assembly contribute to cell dys-
function? Is it the formation of insoluble tau aggregates that
is pathogenic? Although tau loses its activity to stimulate mi-
crotubules, lack of overt phenotype of tau knockout trans-
genic mice [107] suggests that it is very unlikely that tau ab-
normality contributes to neurodegeneration via loss of nor-
mal function due to its hyperphosphorylation. By a series of
studies, we have found that both the abnormally hyperphos-
phorylated tau isolated from AD brain and in vitro hyper-
phosphorylation tau gain a toxic activity to sequester nor-
mal tau and other MAPs, such as MAP1 and MAP2, and
cause microtubule disassembly [16, 18, 66, 108]. Upon de-
phosphorylation, they lose this toxic activity. Polymeriza-
tionofthehyperphosphorylatedtauintoPHFsalsoabolishes
this toxic activity (Alonso A et al, unpublished observation).
Hence, we speculate that the abnormal hyperphosphoryla-
tion of tau causes neurodegeneration by gain of toxic activity
rather than by loss of normal activity that can be compen-
sated for by other MAPs and that formation of PHFs/NFTs
from the hyperphosphorylated tau in neurons is a defense
mechanism by which neurons aim to reduce the toxic activ-
ity of the abnormally hyperphosphorylated tau. This spec-
ulation is supported by recent in vivo studies. Conditional
overexpression of GSK-3β in the transgenic mouse brains in-
ducestauhyperphosphorylationandneurodegeneration,but
no tau aggregation [109]. In contrast, there are NFTs but no
memory loss in several lines of tau transgenic mice (for re-
view, see [110]). This phenomenon is probably common to
other diseases characterized by abnormal protein aggregates
such as Huntington disease and cardiomyopathy, in which
the abnormal, nonﬁbrillar protein oligomers, rather than the
aggregates themselves, appear to be pathogenic [111, 112].
IMBALANCE OF PHOSPHORYLATION/
DEPHOSPHORYLATION IN AD BRAIN
To understand the mechanism leading to abnormal hyper-
phosphorylation of tau in AD, protein kinases and phos-
phatases that regulate tau phosphorylation level must be
identiﬁed ﬁrst. In the last two decades, numerous studies
aimed to the identiﬁcation of tau kinases and phosphatases
have been carried out. It was found that in vitro, dozens
of phosphoseryl/phosphothroenyl protein kinases and most
of the major protein phosphatases could act on tau protein
at various phosphorylation sites (for reviews in detail, see
[82, 113, 114]). Tau appears to be a universal substrate for
protein kinases and phosphatases in vitro. This may not be
surprising, because nearly 20% of the amino acid residues of
tau molecule are serines and threonines, and nearly 50% of
these residues are phosphorylated to certain degrees in AD4 Journal of Biomedicine and Biotechnology
brain (see [82] for review). However, it is unlikely that all
these enzymes that act on tau in vitro catalyze tau phospho-
rylation/dephosphorylation in vivo. Immunohistochemical
studiesalsohaveshownacolocalizationofmorethanadozen
protein kinases and several protein phosphatases with NFTs
of AD brain. As we now know that NFTs are very “sticky”
structuresthatcanbestainedimmunohistochemicallybyan-
tibodies to numerous antigens, immunohistochemical colo-
calization with NFTs can only support other data that indi-
cate a role of the speciﬁc protein or enzyme in the formation
of NFTs, but itself cannot indicate such a role.
Further studies in cultured cells, in situ, and especially in
vivo suggest that a few protein kinases and phosphatases may
beinvolvedinregulationoftauphosphorylationinthebrain.
The kinases that most likely play a role in phosphorylation of
tau in the brain include glycogen synthase kanase-3β (GSK-
3β), cyclin-dependent kinase 5 (cdk5), cAMP-dependent
protein kinase (PKA), stress-activated protein kinases, and
calcium/calmodulin-dependent kinase II (CaMK-II). John-
son and Stoothoﬀ [115] have critically discussed this issue.
The sites of tau phosphorylation by these kinases, except
stress-activity protein kinases, have been summarized in our
recent review [82]. Among protein phosphatases, PP2A has
been shown to be the major tau phosphatase in the brain
[69, 116–120]. In a recent study, we compared the catalytic
kinetics of tau dephosphorylation by various major brain
protein phosphatases and determined the relative contribu-
tions of these phosphatases to the regulation of tau phos-
phorylation quantitatively. We found that PP2A accounts for
∼70% of the total tau phosphatase activity, whereas PP1,
PP2B, and PP5 each accounts for only ∼10% of the total tau
phosphatase activity [88]. Because PP2B activity is upregu-
lated rather than downregulated in AD brain, it is unlikely
that it regulates tau phosphorylation in vivo [121].
Accumulated evidence indicates that tau phosphoryla-
tion is regulated by several protein kinases and that more
than one kinase might be involved in abnormal hyperphos-
phorylation of tau in AD brain. Interestingly, GSK-3β phos-
p h o ry l a t e st a ua tb o t hp r i m es i t e s( i e ,t a un e e d st ob ep r i m e d
byphosphorylationwithotherkinasesatothersites)andun-
primed sites [122–126]. In a cotransfection study, Cho and
Johnson [125] found that a GSK-3β mutant (GSK-3β-R96A)
that only phosphorylates unprimed sites has no negative im-
pact on tau’s ability to bind to microtubules, in contrast to
wild-type GSK-3β, which signiﬁcantly impairs tau’s ability
to bind to microtubules. Further studies demonstrate that
primed phosphorylation of tau at Thr231 by GSK-3β plays
a critical role in decreasing tau’s ability to both bind to and
stabilize microtubules [126]. In rat brains, activation of PKA
not only induces primed phosphorylation of tau by GSK-3β,
but also impairs the spatial memory of rats [124, 127]. GSK-
3β appears to be regulated by both phosphoinositol-3 kinase
and protein kinase C pathways [128–131].
Anobvious approachto understanding how taubecomes
abnormally hyperphosphorylated in AD is to study whether
tau kinase(s) or tau phosphatase(s) are dysregulated in AD
brain. Several studies have focused on whether the activi-
ties and expression of these enzymes are altered in AD brain.
Among protein kinases, cdk5 was reported to be upregulated
in AD brain by one laboratory [132], but this result was chal-
lenged by others [133–136]. On the other hand, both the ac-
tivity and the expression of PP2A as well as the activities of
PP1 and PP5 are decreased in the selected areas of AD brain
[83–89]. Consistent with this ﬁnding, several other neuronal
proteins such as neuroﬁlaments, MAP1B, β-tubulin, and β-
catenin are also hyperphosphorylated in AD brain [24–27].
Hence, it appears that downregulation of the phosphatases,
especially of PP2A, might underlie the abnormal hyperphos-
phorylation of tau and other proteins in AD brain. Studies
of metabolically active rat brain slices and transgenic mice
suggest that the downregulation of PP2A may produce hy-
perphosphorylation of tau, not only by the deﬁcient dephos-
phorylation of tau, but also through the activation of sev-
eral PP2A-regulated protein kinases, including PKA [137],
CaMK-II [138], MAP kinases, and stress-activated protein
kinases [139–141]. Nevertheless, inhibition of PP2A activity
in animal brain could only induce hyperphosphorylation of
tau at some of the hyperphosphorylation sites seen in PHF-
tau, but does not result in NFTs. Attempts to produce mas-
sive tangles of PHFs in animal models merely via alteration
of tau phosphatase and/or kinase activities have not yet been
successful. These observations suggest that the downregula-
tion of tau phosphatases in AD brain may be only partially
responsible for the abnormal hyperphosphorylation of tau.
The causes leading to decreased PP2A activity in AD
brain are not well understood. Downregulation of PP2A
expression [85] and upregulation of PP2A endogenous in-
hibitor proteins IPP2A
1 and IPP2A
2 [142]i nA Db r a i nm a y
both contribute to the downregulation of PP2A activity. Be-
cause the activities of PP1 [83, 88] and PP5 [88, 89], which
contribute to regulation of tau phosphorylation to a much
smaller extent than PP2A [88], are also decreased in AD
brain, there might be a common factor that downregulates
the activities of the major brain protein phosphatases in AD
brain.
In addition to tau kinases and phosphatases, alter-
ations of tau itself, the substrate of these enzymes, may
also play an important role in its abnormal hyperphos-
phorylation and conversion into PHFs. Tau is also mod-
iﬁed post-translationally by β-N-acetylglucosamine (Glc-
NAc) via a glycosidic bond at the hydroxyl groups of serine
and/or threonine residues, and this modiﬁcation is called O-
GlcNAcylation [143–145]. Because O-GlcNAc could modify
the same serine or threonine residues of tau as phosphate
does and a reciprocal relationship between O-GlcNAcylation
and phosphorylation has been seen in many proteins (for re-
view, see [146]), O-GlcNAcylation could aﬀect phosphoryla-
tion of tau. Recent studies in various systems found that tau
phosphorylation is indeed regulated by O-GlcNAcylation in-
versely [144, 145, 147]. Most interestingly, fasting of mice in-
duces downregulation of tau O-GlcNAcylation, which relies
on glucose metabolism to supply UDP-GlcNAc as a donor
for protein O-GlcNAcylation, and in turn leads to hyper-
phosphorylation of tau [145]. These ﬁndings led to the novel
hypothesis that impaired glucose uptake/metabolism in AD
brain, which was well established decades ago, contributesCheng-Xin Gong et al 5
Abnormally hyperphosphorylated tau
Sequestration of normal
tau and other MAPs
Disassembly of MTs
Axoplasmic ﬂow ↓
Retrograde degeneration
(loss of synapse)
Death of neurons
Dementia
Detached from MTs
Intraneuronal tau ↑
Late PHFs/NFTs
Truncation
Nitration
Polyamination
Glycation
Ubiquitination
Early PHFs/NFTs
Abnormal tau N-glycosylation
Tau O-GlcNAcylation ↓ Glucose uptake/metabolism ↓
Dysregulation of phosphorylation/dephosphorylation
Normal tau
Figure 1: Proposed mechanism of neuroﬁbrillary degeneration. MAPs, microtubule-associated proteins; MTs, microtubules; PHFs, paired
helical ﬁlaments; NFTs, neuroﬁbrillary tangles.
to the disease pathogenesis via downregulation of tau O-
GlcNAcylation and, consequently, upregulation of tau phos-
phorylation that leads to neuroﬁbrillary degeneration [148].
Classical N-linked glycosylation is a modiﬁcation of pro-
tein at asparagine residues by oligosaccharides, which nor-
mally modiﬁes only membrane proteins and secreted pro-
teins. Tau in AD brain, but not in normal human brain, was
found to be modiﬁed by N-glycosylation [68, 149, 150], and
this aberrant tau modiﬁcation appears to precede and facili-
tate abnormal hyperphosphorylation of tau [150–152]. This
modiﬁcation has been reviewed in detail in a recent article
[82].
MECHANISM OF NEUROFIBRILLARY DEGENERATION
There is no doubt that the abnormality of tau plays a cen-
tral role in neuroﬁbrillary degeneration in AD and other
tauopathies. A critical review of the literature accumulated
in the last two decades sheds light onto the probable mecha-
nism of neuroﬁbrillary degeneration of AD (Figure 1).
Tau is the major microtubule-associated protein of ma-
ture neurons where it stimulates microtubule assembly and
stabilizes microtubule structure. Tau is normally modiﬁed
by both phosphorylation and O-GlcNAcylation. The phos-
phorylation level of tau is regulated by tau kinases and tau
phosphatases, as well as by the alteration of tau itself. In
AD and probably also in other tauopathies, metabolic and
genetic abnormalities lead to dysregulation of signal trans-
duction pathways, which in turn causes an imbalance of the
phosphorylation/dephosphorylation system, that is, down-
regulation of PP2A in the brain. This imbalance results in in-
creased phosphorylation (ie, hyperphosphorylation) of tau.
The impaired brain glucose uptake/metabolism that pre-
cedes AD also facilitates hyperphosphorylation of tau via
downregulation of tau O-GlcNAcylation [148]. Aberrant N-
glycosylation of tau in AD brain also makes tau a more favor-
able substrate for major tau kinases and less favorable for tau
phosphatases [151, 152], thereby facilitating tau hyperphos-
phorylation.
The abnormally hyperphosphorylated tau resulting from
any of the above causes not only loses its biological activ-
ity to stimulate microtubule assembly, but also becomes a
toxic molecule, sequesters normal tau, MAP1, and MAP2,
and causes disassembly of microtubules. The breakdown of
the microtubule network in the aﬀected neurons compro-
mises axonal transport and leads to retrograde degeneration,
which in turn results in neuronal death and dementia. On
theotherhand,theabnormallyhyperphosphorylatedtaude-
tached from microtubules is not only easier to polymerize
into PHFs as a result of hyperphosphorylation, but it also
causesincreasedintraneuronalsolubletauconcentrationdue
to sequestration of normal tau from microtubules, which
further facilitates tau aggregation into PHFs. The polymer-
ized abnormal tau is further modiﬁed by ubiquitination, gly-
cation, polyamination, nitration, and truncation (for review,
see [82]), and forms mature PHFs/NFTs. Unlike the unpoly-
merized hyperphosphorylated tau that is toxic, PHFs/NFTs
appears to be inert (Alonso A et al unpublished observa-
tion), but these lesions grow in size with disease progression6 Journal of Biomedicine and Biotechnology
and eventually might physically choke the aﬀected neuron to
death.
THERAPEUTIC TARGET TO TREAT AD BY CORRECTING
DYSREGULATION OF PROTEIN PHOSPHORYLATION/
DEPHOSPHORYLATION
Because neuroﬁbrillary degeneration plays a central role in
the pathogenesis of AD, one of the most attractive thera-
peutic targets of AD is to inhibit neuroﬁbrillary degenera-
tion. As outlined in Figure 1, the most promising approaches
to achieve this goal are to inhibit the abnormal hyperphos-
phorylation of tau and to inhibit its sequestration of nor-
mal MAPs. The former approach is more eﬀective since it
should both rescue the disruption of microtubule and axo-
plasmic ﬂow and prevent further deposition of NFTs. Sev-
eral academic groups and pharmaceutical companies have
been investigating this approach by restoring PP2A activ-
ity or inhibiting tau kinase activity in the brain. Meman-
tine, a low-to-moderate-aﬃnity antagonist of NMDA recep-
tor, which improves mental function and the quality of daily
life of individuals with moderate to severe AD [153, 154],
reverses the okadaic-acid-induced inhibition of PP2A activ-
ity and prevents tau hyperphosphorylation in hippocampal
slice cultures from adult rats [155]. The restoration of PP2A
activity to normal level by memantine also leads to restora-
tion of the expression of MAP2 in the neuropil and a rever-
sal of hyperphosphorylation and accumulation of neuroﬁl-
aments. Wang’s group has demonstrated that treatment of
brain slices and rats with melatonin can restore PP2A activ-
itythatisinhibitedbyokadaicacidorcalyculinAandreverse
hyperphosphorylation of tau and neuroﬁlament proteins as
well as cytotoxicities [156–158]. Melatonin also prevents tau
hyperphosphorylation and aggregation induced by overac-
tivation of GSK-3 or PKA [131, 159]. These are examples
showingthatinhibitionofdysregulationofproteinphospho-
rylation/dephosphorylationisapromisingtargettotreatAD.
Further investigation of new compounds that can inhibit ab-
normal hyperphosphorylation of tau will likely provide new
treatments for AD.
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